Patents by Inventor Naveed Shams

Naveed Shams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200345713
    Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
    Type: Application
    Filed: December 27, 2018
    Publication date: November 5, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
  • Publication number: 20200289483
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Patent number: 10702511
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 7, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20190105310
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: December 6, 2018
    Publication date: April 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi Kawata, Noriko Kawabata
  • Patent number: 10179127
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: January 15, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20180169079
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Application
    Filed: February 13, 2018
    Publication date: June 21, 2018
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Patent number: 9943510
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 17, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20160324838
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Application
    Filed: July 18, 2016
    Publication date: November 10, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed SHAMS, Henk-Andre KROON, Hisashi KAWATA, Noriko KAWABATA
  • Patent number: 9415038
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 16, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Publication number: 20150196541
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Application
    Filed: January 8, 2015
    Publication date: July 16, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • Patent number: 8911426
    Abstract: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: December 16, 2014
    Assignee: On Demand Therapeutics, Inc.
    Inventors: Jonathan Robert Coppeta, Kenneth N. Horne, John T. Santini, Jr., John A. Scholl, Gregory J. R. Spooner, Cynthia L. Stevenson, Naveed Shams, Andrew Poutiatine
  • Patent number: 8470792
    Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: June 25, 2013
    Assignee: Opko Pharmaceuticals, LLC.
    Inventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
  • Publication number: 20120035528
    Abstract: An implantable drug delivery device that uses multiple reservoir elements to contain and release doses of active pharmaceutical ingredients. The device includes a first shell element, which has a first enclosed cavity volume and forms a low-permeability barrier. The first shell element is configured to absorb light irradiation from a laser source, the laser irradiation causing a breach in the first shell element. A first active pharmaceutical ingredient is contained in the first enclosed cavity volume and is released when the first shell element is breached. The device also includes a second shell element, which has a second enclosed cavity volume and also forms a low-permeability barrier. A second active pharmaceutical ingredient is contained in the second enclosed cavity volume. The device also includes an envelope element containing the first and second shell elements.
    Type: Application
    Filed: February 8, 2011
    Publication date: February 9, 2012
    Applicants: MicroCHIPS, Inc., On Demand Therapeutics, Inc.
    Inventors: Jonathan R. Coppeta, Kenneth N. Horne, John T. Santini, JR., John A. Scholl, Gregory J.R. Spooner, Cynthia L. Stevenson, Naveed Shams, Andrew Poutiatine
  • Publication number: 20120009185
    Abstract: A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration.
    Type: Application
    Filed: September 19, 2011
    Publication date: January 12, 2012
    Applicant: Genentech, Inc.
    Inventor: Naveed Shams
  • Publication number: 20100151007
    Abstract: Disclosed herein are siRNA compositions and methods useful for inhibiting expression of vascular endothelial growth factor (VEGF) isoforms. Such compositions and methods further involve siRNA capable of selectively targeting angiogenic VEGF isoforms while selectively sparing anti-angiogenic isoforms. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering small interfering RNAs as disclosed.
    Type: Application
    Filed: December 4, 2009
    Publication date: June 17, 2010
    Applicant: OPKO OPHTHALMICS, LLC
    Inventors: Phillip Frost, Nadine Dejneka, Ottrina S. Bond, Naveed Shams
  • Publication number: 20100111963
    Abstract: A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration.
    Type: Application
    Filed: November 9, 2007
    Publication date: May 6, 2010
    Applicant: Genentech, Inc.
    Inventor: Naveed Shams
  • Publication number: 20070190058
    Abstract: A method is provided for administering to a mammal suffering from, or at risk for, an intraocular neovascular disorder with regular dosing of a therapeutically effective amount of VEGF antagonist, followed by less frequent dosing of a therapeutically effective amount of VEGF antagonist.
    Type: Application
    Filed: April 20, 2007
    Publication date: August 16, 2007
    Applicant: Genentech, Inc.
    Inventor: Naveed Shams
  • Publication number: 20060121090
    Abstract: Compositions capable of effecting a ‚Äúpharmacological trabeculocanalotomy‚ÄĚ in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.
    Type: Application
    Filed: January 20, 2006
    Publication date: June 8, 2006
    Inventors: Bruce Pfeffer, Rosemarie Flick, Naveed Shams, Stephen Bartels
  • Patent number: RE48183
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: September 1, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata